about
Neurophysiology of lower urinary tract function and dysfunctionInducible knockout mutagenesis reveals compensatory mechanisms elicited by constitutive BK channel deficiency in overactive murine bladder.Effect of Suo Quan Wan on the bladder function of aging rats based on the β-adrenoceptor.Human atrial β(1L)-adrenoceptor but not β₃-adrenoceptor activation increases force and Ca(2+) current at physiological temperature.Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trialThe Impact of Gene Polymorphisms on the Success of Anticholinergic Treatment in Children with Overactive Bladder.Beta-3 adrenergic receptors could be significant factors for overactive bladder-related symptomsPersistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in CanadaDevelopments in pharmacological therapy for the overactive bladder.Current and emerging investigational medical therapies for the treatment of overactive bladder.BRL37344, a β3-adrenergic receptor agonist, decreases nerve-evoked contractions in human detrusor smooth muscle isolated strips: role of BK channels.Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies.Mirabegron: a review of its use in patients with overactive bladder syndrome.Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).Mirabegron in the treatment of overactive bladder.Neurogenic bladder: from diagnosis to management.Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.Current and future pharmacotherapy for treating overactive bladder.Human brown adipose tissue as a target for obesity management; beyond cold-induced thermogenesis.Changes in Awake Cystometry and Expression of Bladder β-adrenoceptors after Partial Bladder Outlet Obstruction in Male Rats.Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder.Evidence for the presence of beta-3-adrenoceptors mediating relaxation in the human oviduct.Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β3 -Adrenoceptor Agonist, in Japanese Patients with Overactive Bladder.Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study.Non-adrenergic, non-cholinergic, non-purinergic contractions of the urothelium/lamina propria of the pig bladder.β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.Combined treatment with a β3 -adrenergic receptor agonist and a muscarinic receptor antagonist inhibits detrusor overactivity induced by cold stress in spontaneously hypertensive rats.Loss of adenosine A2B receptor mediated relaxant responses in the aged female rat bladder; effects of dietary phytoestrogens.Efficacy and Safety of the Selective β3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study.Bladder selectivity of the novel β₃-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat.Investigation of Drug-Drug Interactions Between Ritobegron, a Selective β3 -Adrenoceptor Agonist, With Probenecid in Healthy Men.Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: An immunohistochemical study.The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study.
P2860
Q24550931-DF1F80F0-F3E9-4252-AE61-B2C49FC61B78Q33630889-BC4918FD-43FA-4F3D-9709-CAD350F24AE1Q33744606-EC73E977-BBF2-42A6-AF0D-57E6A7E6F9D9Q34588659-2EAD7215-55B5-4A6D-813B-9A68C9669216Q34991783-7B5BCD10-9276-4E78-9D2C-66B6DE508642Q35807255-E5AF79FA-C619-46A0-A009-6BDA7D4CABD2Q36262124-9650E268-AFD3-4CD5-9131-B8AE7D8E4E6EQ36326096-E59143B5-49AB-49C7-B5BF-6BC36CDE734CQ36566857-018552A1-B85A-4EAD-B5DC-7665F103C566Q36568728-2B39BF03-8AB6-472C-804E-BCA0F9483B71Q37136287-0D5A07D3-62D9-4E3B-B619-60434B2165FCQ37432115-4C116763-7B5D-452A-9616-E1F148C51FE2Q38118658-CDF693FB-D881-4B82-A4E3-A31BDC4FF47BQ38152756-52415421-3A91-4FE7-83C3-AF91204CFC95Q38193896-1CC06BF5-1D18-4F25-86D4-EDA4DF0439B4Q38197276-CB3FD6CB-4AB4-4DF6-832A-BA6636DB60BBQ38239524-CF349708-B82D-49E7-A47E-65F7229B1D48Q38570412-7329F5E4-423E-4236-8CA2-098F59709F64Q38577301-8AC371AC-1B62-4D60-B58E-A420556C5EE0Q38851523-16023EE2-68C7-40CE-BAD2-37B83E7548E5Q39434608-1B580862-C442-41C7-9525-7AC3BABE4782Q41161533-2DC551EB-ED8F-4C01-AACA-9AFAE27AFE6DQ43928336-15CDE068-70D7-466B-A474-1BF685D8D902Q46103322-56CE0617-EAEF-4FCD-9161-3A8558DB5592Q46398937-9516AE8D-09A8-448E-9EE0-DF2CB1090BACQ47585163-FE9F66FB-93C5-4C9C-981E-104421851252Q47784907-C5866449-DA42-4F45-89A8-8FC7B80E97E6Q48129599-D2BBCE2E-5DA7-41DF-B6CF-5637287F0F94Q48342307-6831F375-B025-4013-94BA-273EF9AF0721Q50881227-9841FC95-9BB2-4593-9234-DAC48582C70CQ51368805-03B81DF9-77E1-48E5-8682-003965A74F27Q51607907-AB525F75-4019-4CAD-B06F-3F8ECC390121Q51759362-07C5BF4E-0FCF-4D7C-815F-C4CE06B812C3Q53102994-E0C94E18-3CE2-4ED8-BDBB-C10C2C9C74C6Q53630970-5C13B9E7-6B2A-4198-944A-CEC6F3561514Q53778752-41244B91-410F-4F0C-B5C7-1B71A9497CC4Q55429410-2B97CAFE-DC11-4D2A-97F7-3A2BB6F3B0BA
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Beta3-adrenoceptors in human detrusor muscle.
@ast
Beta3-adrenoceptors in human detrusor muscle.
@en
Beta3-adrenoceptors in human detrusor muscle.
@nl
type
label
Beta3-adrenoceptors in human detrusor muscle.
@ast
Beta3-adrenoceptors in human detrusor muscle.
@en
Beta3-adrenoceptors in human detrusor muscle.
@nl
prefLabel
Beta3-adrenoceptors in human detrusor muscle.
@ast
Beta3-adrenoceptors in human detrusor muscle.
@en
Beta3-adrenoceptors in human detrusor muscle.
@nl
P1433
P1476
Beta3-adrenoceptors in human detrusor muscle.
@en
P2093
Osamu Yamaguchi
P356
10.1016/S0090-4295(01)01635-1
P407
P433
P577
2002-05-01T00:00:00Z